Identifying Novel Biomarkers of Cerebral Ischemia through the Use of Mass Spectroscopy (S15.004)

CONCLUSIONS: Mass spectroscopy-based proteomics is a potential new tool to help identify biomarkers for cerebral ischemia. Ultimately, a panel of proteins may serve as a marker for cerebral ischemia or TIA. We have identified three candidate proteins as possible indicators for cerebral ischemia. Larger studies are needed to confirm our results. Study Supported by: Stanford Cardiovascular Institute; American Brain Foundation and American Academy of Neurology Clinical Research Training FellowshipDisclosure: Dr. George has nothing to disclose. Dr. Adams has nothing to disclose. Dr. Mlynash has nothing to disclose. Dr. Kjaergaard has nothing to disclose. Dr. Kuo has nothing to disclose. Dr. Kemp has nothing to disclose. Dr. Garcia has nothing to disclose. Dr. Albers has received personal compensation for activities with Genentech, Inc., and Lundbeck Research USA Inc. Dr. Albers has received research support from Genentech Inc., Aventis Pharmaceuticals Inc., Sanof-Aventis Pharmaceuticals, Inc., Biogen Idec, Ono Pharmaceutical, and AstraZeneca Pharmaceuticals. Dr. Olivot has nothing to disclose.

Source: Neurology - April 9, 2014 Category: Neurology Authors: George, P., Adams, C., Mlynash, M., Kjaergaard, C., Kuo, C., Kemp, S., Garcia, M., Albers, G., Olivot, J.-M. Tags: Cerebrovascular Disease and Interventional Neurology: Clinical and Imaging Biomarkers and Genetics Source Type: research